No Data
No Data
Yirui Biotech: Summary of the 2024 Semi-Annual Report
Yirui Biotech: 2024 Semi-Annual Report
Yirui Bio (300942.SZ) released its performance for the first half of the year, with a net loss of 1.5595 million yuan.
Yirui Biotechnology (300942.SZ) released its 2024 interim report. During the reporting period, the company achieved revenue...
In the first half of the year, Yirui Biological (300942.SZ) reported a net loss of 1.5595 million yuan.
On August 29, 8ainlin announcemented the interim report for the first half of 2024, with operating revenue of 0.104 billion yuan, a year-on-year decrease of 7.55%; net profit attributable to shareholders of listed companies -1.5595 million yuan, a narrower year-on-year loss; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was -5.2591 million yuan; and basic earnings per share was -0.0039 yuan.
What Shenzhen Bioeasy Biotechnology Co., Ltd.'s (SZSE:300942) P/S Is Not Telling You
Yirui Biotechnology (300942.SZ): The company's in vitro diagnostic business has greatly shrunk. Currently, the company is focusing on steady development of the food safety rapid detection business.
Yirui Biology (300942.SZ) stated on its investor platform on July 16th that its in vitro diagnostic business has greatly shrunk, and the company is currently focusing on the steady development of its food safety rapid detection business. The main reason for the loss in the first quarter was the shrinkage of the in vitro diagnostic business and the influence of seasonal factors on the income of the food safety business, but the corresponding fixed costs such as rent and personnel wages remained at a certain level.
No Data